Meta-analysis of 3 RCTs (14,239 patients) after noncardioembolic ischaemic stroke or TIA: FXIa inhibitors added to antiplatelets vs placebo cut any stroke (RR 0.75) without a clear rise in major bleeding (RR 1.12, 95% CI 0.87-1.44). Results driven by one phase 3 trial.
Meta-analysisn = 14,239
Katsanos et al. Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-Analysis